Percutaneous left atrial appendage closure in patients with prior intracranial bleeding and thromboembolism

BACKGROUND Percutaneous left atrial appendage closure (LAAC) is an alternative treatment in atrial fibrillation patients with contraindication to oral anticoagulation. However, patient selection criteria for LAAC are debated. OBJECTIVE The purpose of this study was to evaluate the outcome after LAAC in patients with prior intracranial bleeding and thromboembolism. METHODS Consecutive patients with atrial fibrillation and prior intracranial bleeding who underwent LAAC from February 2009 to August 2018 at the Turku University Hospital, Finland, were included in a prospective registry. Patients were followed through clinical visits and annual phone calls up to 5 years. RESULTS Overall 104 patients (mean age 73 +/- 7 years; 30% women; CHA2DS2-VASc score 4.7 +/- 1.4; HAS-BLED score 3.3 +/- 0.9) with atrial fibrillation and prior intracranial bleeding underwent successful LAAC using mainly (n 5 102) Amplatzer devices. Median time from intracranial bleeding to LAAC was 7 months, and median follow-up 3.6 years. Antithrombotic treatment was <= 6 months in 71 patients (68%), and 48 patients (46%) received aspirin or clopidogrel alone. The rates of thromboembolism and intracranial bleeding (per 100 patient-years) were 3.4 and 1.9, respectively. In 39 patients with previous thromboembolism, the rate of thromboembolism was 3.6 per 100 patient-years (95% confidence interval 1.5-7.0), yielding a 69% relative risk reduction with respect to predicted risk based on median CHA2DS2-VASc score. Overall, rates of thromboembolism and intracranial bleeding were broadly similar in patients with and those without prior thromboembolism. CONCLUSION Percutaneous LAAC with minimized antithrombotic treatment was demonstrated to be a valid treatment option in high-risk patients with prior intracranial bleeding and thromboembolism.